Fluorescence Lifetime Imaging Enables In vivo Quantification of PD-L1 Expression and Inter-tumoral Heterogeneity.

Patient selection for cancer immunotherapy requires precise, quantitative readouts of biomarker expression in intact tumors that can be reliably compared across multiple subjects over time. The current clinical standard biomarker for assessing immunotherapy response is programmed death-ligand-1 (PD-L1) expression, typically quantified using immunohistochemistry. This method, however, only provides snapshots of PD-L1 expression status in microscopic regions of ex vivo specimens.

An evaluation by dental clinicians of cutting characteristics and haptic perceptions in 3D-printed typodont teeth: A pilot study.

Objectives: This study aimed to compare the haptic perception of clinicians to the cutting response of 3D-printed typodont teeth and commercial typodont teeth and human extracted teeth.

Methods: Twenty clinicians were asked to perform a Class I cavity preparation on commercial typodont teeth, 3D-printed typodont teeth, and human extracted teeth, while the forces were recorded via a three-axis load cell. The haptic perception of clinicians was also evaluated through a response questionnaire comparing commercial and 3D-printed typodont teeth.

Miniaturized Fab' imaging probe derived from a clinical antibody: Characterization and imaging in CRISPRi-attenuated mammary tumor models.

Clinical imaging-assisted oncosurgical navigation requires cancer-specific miniaturized optical imaging probes. We report a near-infrared (NIR) Fab'-based epidermal growth factor receptor (EGFR)-specific probe carrying 3 NIR fluorophores (Fab'-800CW), which retained high-affinity binding to EGFR ectodomain (equilibrium K  = 1 nM). Fab'-800CW showed a robust 4-times gain of fluorescence intensity (FI) and a 20% lifetime (FLT) increase under the conditions mimicking intracellular degradation.

Computational identification of potential tau tubulin kinase 1 (TTBK1) inhibitors: a structural analog approach.

Unlabelled: Abnormal deposition or aggregation of protein alpha-synuclein and tau in the brain leads to neurodegenerative disorders. Excessive hyperphosphorylation of tau protein and aggregations destroys the microtubule structure resulting in neurofibrillary tangles in neurons and affecting cytoskeleton structure, mitochondrial axonal transport, and loss of synapses in neuronal cells. Tau tubulin kinase 1 (TTBK1), a specific neuronal kinase is a potential therapeutic target for neurodegenerative disorders as it is involved in hyperphosphorylation and aggregation of tau protein.